Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Canada clears Cyberonic's VNS (vagus nerve stimulation) therapy for depression:

This article was originally published in Clinica

Executive Summary

Cyberonics has gained the go-ahead in Canada to market its implantable vagus nerve stimulation (VNS) device for the treatment of chronic or recurrent depression. The NeuroCybernetic Prosthesis system, which is indicated for use in patients who are resistant or intolerant, can now be targeted at around 100,000 Canadians who suffer form the condition, says the Houston, Texas company. The product first became available as a treatment for depression in Europe last month (see Clinica No 950, p 17).

Topics

UsernamePublicRestriction

Register

MT070813

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel